Navigation Links
Lazarus Effect Closes $5 Million Financing
Date:7/31/2014

CAMPBELL, Calif., July 31, 2014 /PRNewswire/ -- Lazarus Effect, a medical device company focused on the development of novel interventional devices to facilitate removal of blood clots, announced the closing of a $5 million financing. Proceeds from the financing will support EU commercialization of several approved Lazarus Effect devices, as well as regulatory filings for the Lazarus ReCover™ and Lazarus Cover™ in the United States.

"This financing reflects investor confidence in the value of our novel, platform technology as well as our recent IP and regulatory progress," said Martin Dieck, chairman and CEO, Lazarus Effect. "Our expert team has a track record of bringing high-value neurointerventional products to market, and we are grateful to our investors for helping us replicate this success with Lazarus Effect."

Lazarus Effect is developing a complete portfolio of vascular-device products to facilitate removal of blood clots based on a patented, wire-frame technology platform. The company currently has five issued US patents and numerous pending US and worldwide patent applications. The Lazarus Funnel™ Guide Catheter and Lazarus ReCover devices have CE Mark for use in Europe, and the Funnel is cleared for use in the United States. The Lazarus Cover is pending CE Mark. Neither the ReCover nor the Cover are approved for sale in the United States.

New findings from a study evaluating the ability of the Lazarus Cover to prevent emboli during clot retrieval versus the current standard were presented today at the Society of Neurointerventional Surgery (SNIS) 11th Annual Meeting in Colorado Springs, CO.  Alexander Khalessi, MD, MS, director of Endovascular Neurosurgery and surgical director of Neurocritical Care at the University of California, San Diego, shared data from simulated thrombectomy procedures performed in an anatomical model which demonstrated that the Lazarus Cover can protect captured embolic material during withdrawal, potentially reducing the risk of embolization.

Forward-looking Statements

Statements contained in this press release about Lazarus Effect, Inc. that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include changes in market or financial conditions, and other changes beyond the control of the Company. The Company specifically disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Lazarus Effect
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology
2. Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idecs Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
3. New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice
4. Clinical Trial Demonstrates That EarlySense May Be An Effective Indicator for Respiratory Pattern Recognition
5. New England Journal of Medicine Study Finds Upper-Airway Electronic Stimulation Effective for Obstructive Sleep Apnea
6. ObamaCare: Health Care Reform and its Effect on Sleep Apnea
7. Improving the Quality and Effectiveness of Marketing Services Groups in an Environment Characterized by Globalization and Shrinking Resources
8. New England Journal of Medicine releases study showing GSKs FluLaval Quadrivalent vaccine effective in preventing seasonal flu in children
9. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Frost & Sullivan Applauds Definiens Strong Technology Portfolio for the Effective Data Analysis of Histology Images
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):